A medication that is used to control blood glucose control in people with diabetes is now set to help prevent or help slow kidney disease, resulting in millions of deaths per year and hundreds of thousands of people being needed to remain in dialysis .
Daughters say it's hard to grasp the importance of this study, and what it means is the problem of this problem, which is growing because of the epidemic.
The study investigated Janssen Pharmaceuticals' drug Invokana. Results were visited on Sunday at a medical meeting in Australia and published by the New England Journal of Medicine.
About 30 million Americans and more than 420 million people have diabetes worldwide, and most cases are Type 2, the type of induction. It happens if the body does not make enough or can use insulin well, that changes the food in the energy.
This can cause the kidneys to over time, cause and eventually fail. In the United States, it is responsible for nearly half a million people who need dialysis and thousands of renal plants every year.
Some blood pressure threatens this risk but they are only effective for one part. The new study, researched Invokana, a clever pellet sold now to help with blood sucker checks, to see if it also promoted kidney disease as a supplement to standard treatments.
For the study, about 13,000 people with Type 2 diabetes and chronic kidney cancer were offered from Invoro or dummy pills. Independent monitors stopped studying, after 4,400 people had been treated for an average of 2.5 years, so it was obvious that the drugs were helping.
These at-risk drugs had a 30% lower risk of any of these problems – renal impairment, need for dialysis, need for kidney transplantation, deaths of natural or pre-formed causes, or other signs that the kidneys fall .
For every 1000 people the medicine took 2.5 years, there would be 47 less cases of one of these problems, researcher estimates.
Serious side-effect rates were similar in medicine and plaque farmers, such as laying, over or over removal, a concern created by an earlier study by Invotra. One side effect, when the body does not make enough of it, became more and more common in Invotra, but rarely common.
Janssen, who is part of Johnson & Johnson, sponsored the study and worked or consulted many authors for the company. The drugs cost as much as $ 500 a month in & # 39; US out-of-pocket costs for patients may vary, depending on insurance.
The importance of this great and well-done study "cannot be overstated," Drs. Julie Ingelfinger and Clifford Rosen, editors of the medical journal, wrote in a guiding article.
In the past few years, several studies have found that Invotra and some similar medicines can be at risk. The new results, which you can prevent or prevent Invokana from expanding, extend the potential benefits of drugs.
Marilynn Marchione can follow http://twitter.com/MMarchioneAP
The Associated Press Social Sciences is supportive of the Howard Hughes Medical Institute's Department of Science Education. The AP is only responsible for all content.